Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BiPar Sciences Inc.

Division of Sanofi
www.biparsciences.com

Latest From BiPar Sciences Inc.

AntriaBio appoints Barry Sherman to board

AntriaBio, a biopharmaceutical company focused on developing treatments for diabetes and metabolic diseases, has named Dr Barry Sherman to its board of directors. Notably, Dr Sherman was the first chief medical officer of Genentech in the mid-1990s following his role directing Genentech's clinical research and medical affairs teams. He has also served as president and CEO of StemPar Sciences, president and CEO of Anergen Inc, a founder of Pain Therapeutics, and the executive vice-president and co-founder of BiPar Sciences.

Metabolic Disorders Neurology

Sanofi Oncology’s Transformation Rests On Fedratinib, At Least In The Near-Term

The JAK2 inhibitor for myelofibrosis is the company’s most advanced oncology candidate and will be an anchor for Sanofi as it looks to build a portfolio of next-generation cancer drugs after the late-stage failure of the PARP inhibitor iniparib.

BioPharmaceutical Clinical Trials

Sanofi: €4bn hinges on data due by October

Late-stage data on Sanofi pipeline drugs potentially worth more than €4 billion in annual sales are accumulating, and the next six months will be critical. There are five key Phase III read-outs due by the end of the third quarter, meaning that by October the French firm's mid-term growth potential could look a lot clearer.

Metabolic Disorders Cardiovascular

CytomX hires Hoyoung Huh to chair board

CytomX Therapeutics, a biotechnology company developing monoclonal antibody therapies, has appointed Dr Hoyoung Huh chair of the board of directors. Dr Huh currently serves as chair of Geron Corporation, and on the boards of Addex Pharmaceuticals and BayBio. He was previously CEO, president and chair of BiPar Sciences, which was acquired by Sanofi in 2009. Former CytomX chair Dr Charles Homcy, venture partner at Third Rock Ventures, will continue to serve on the board.

See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Sanofi
  • Senior Management
  • Atul Dhir, MD, PhD, CEO
    Charles Bradley, PhD, VP, Clinical Dev.
  • Contact Info
  • BiPar Sciences Inc.
    Phone: (650) 635-6050
    1000 Marina Blvd.
    Ste. 550
    Brisbane, CA 94005
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register